Smith+Nephew announces its efforts to develop technology in the field of Spatial Surgery – a new frontier in arthroscopic surgical innovation. Smith+Nephew has submitted to the FDA a traditional 510(k) for a technology called the TESSA Spatial Surgery System. If cleared by the FDA, TESSA would combine a real-time, tracking-enabled device powered by a NVIDIA GPU. By using video processing and augmented reality guidance, TESSA would assist a surgeon in making anterior cruciate ligament reconstruction femoral tunnel decisions by navigating an operative plan.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SNN:
- Smith & Nephew price target raised to 1,300 GBp from 1,250 GBp at Deutsche Bank
- Smith & Nephew Announces Share Capital Details
- Positive Outlook for Smith & Nephew: Buy Rating Driven by Strategic Initiatives and Market Growth Potential
- Smith & Nephew Snats (SNN) Announces Q2 Dividend: Read On for Important Dates
- Smith & Nephew Snats’ Positive Earnings Call Highlights
Questions or Comments about the article? Write to editor@tipranks.com